Connect with us

Projects & Publications



  1. Improving access to preventive health services by developing an analytical laboratory and a pilot neonatal screening program for vulnerable groups, including Roma, SEE AP1.26, 2022-2024
  2. Sequencing as a standard of care in the diagnosis of hemophilia and rare coagulation disorders in Romania, SEE SG2.24, 2022-2024
  3. Strengthening the clinical approach to haemophilia in the northern region of Romania and developing a national register
  4. Continuous Flow Interchange of Communication and Knowledge in Biomedical University Research – FLOW, SEE 21-COP-0034, 2022-2023
  5. Cooperation strategy for knowledge transfer, internationalization, and curricula innovation in the field of research education at the 3rd level of study (AURORA), SEE 21-COP-0049
  6. HE-RO-IS strategic cooperation în Hematology, SEE 19-COP-0031


  1. Validation of epigenetic reprogramming of lung cancer models and anti-cancer activity through serial administration of repositioned 5-Azacytidine, AZUR (PN-III-P4-ID-PCE-2020-1957), 2021-2023
  2. The role of CYP26 in retinoid homeostasis against the background of etiopathogenesis and treatment response for myelodysplastic syndromes, LONDON (PN-III-P4-ID-PCE-2020-1957), 2021-2024
  3. Harnessing the Ubiquitin-Proteasome System (UPS) to Suppress Tumors’ Growth via Manipulating Generation of NF-κB, ROME, (PN-III-P4-ID-PCE-2020-2252), 2021-2024
  4. Supporting a team of young researchers în creating an independent research program based on the Sleeping Beauty protocol to develop CAR T cells, SEATTLE, TE 139/2020 (PN-III-P1-1.1-TE-2019-0271), 2019-2022
  5. Next generation preclinical model for evaluation of microRNA-205-5p therapeutic role în limitation of melanoma metastasis, MELAMIR, PD 122 (PN-III-P1-1.1-PD-2019-0805), 2020-2022
  6. Transfer of knowledge in clinical applications of biogenomics in oncology and related fields – BIOGENONCO” ID P_40_318, in Subsidiary Contract no. 28781/23.09.2020 “Evaluation of the antitumor action and optimization of the composition of the product Nera Plant Vito-complex”, 2020-2022
  7. Advanced preclinical validation of microRNA-205-5p-based therapeutic model for inhibition of epithelial to mesenchymal transition în melanoma metastasis MELAMET, 539PED (PN-III-P2-2.1-PED-2019-3640), 2021-2022
  8. Potential protein biomarkers with utility in the diagnosis of intrahepatic cholangiocarcinoma. PD113/2020 (PN-III-P1-1.1-PD2019-0852), 2020-2022
  9. Stereoselective technologies applicable in the metabolomics of neurological and neurodegenerative diseases – (PN-III-P1-1.1-. PD-2019-0929), 2020-2022


  1. Munteanu R, Feder RI, Onaciu A, Munteanu VC, Iuga CA, Gulei D. Insights into the Human Microbiome and Its Connections with Prostate Cancer. Cancers (Basel). April, 2023, Q2, IF: 5.2.
  2. Faur CI, Dinu C, Toma V, Jurj A, Mărginean R, Onaciu A, Roman RC, Culic C, Chirilă M, Rotar H, Fălămaș A, Știufiuc GF, Hedeșiu M, Almășan O, Știufiuc RI. A New Detection Method of Oral and Oropharyngeal Squamous Cell Carcinoma Based on Multivariate Analysis of Surface Enhanced Raman Spectra of Salivary Exosomes. J Pers Med. April, 2023, Q2, IF:. 3.508
  3. Kegyes D, Gulei D, Drula R, Cenariu D, Tigu B, Dima D, Tanase A, Badelita S, Buzoianu AD, Ciurea S, Ghiaur G, Terpos E, Ciechanover A, Einsele H, Tomuleasa C. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. May , 2023, Q1, IF: 7.35
  4. Gulei D, Drula R, Ghiaur G, Buzoianu AD, Kravtsova-Ivantsiv Y, Tomuleasa C, Ciechanover A. The Tumor Suppressor Functions of Ubiquitin Ligase KPC1: From Cell-Cycle Control to NF-κB Regulator. Cancer Res. Jun, 2023, Q1. IF: 11.2
  5. Cenariu D, Rus I, Bergthorsson JT, Grewal R, Cenariu M, Greiff V, Tigu AB, Dima D, Selicean C, Petrushev B, Zdrenghea M, Fromm J, Aanei CM, Tomuleasa C. Flow Cytometry of CD5-Positive Hairy Cell Leukemia. Mol Diagn Ther. Jun, 2023, Q2, IF 4
  6. Constantinescu C, Constantinescu R, Bergthorsson JT, Greiff V, Tanase A, Colita A, Gulei D, Tomuleasa C. Pitfalls in patenting academic CAR-T cells therapy. Expert Opin Ther Pat. Jun, 2023, Q 1, IF:6.6
  7. Tigu AB, Hotea I, Drula R, Zimta AA, Dirzu N, Santa M, Constantinescu C, Dima D, Bergthorsson JT, Greiff V, Gulei D, Coriu D, Serban M, Mahlangu J, Tomuleasa C. RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. Jul, 2023, Q2, IF: 5.3